Alimetry

Executive Summary

Alimetry is a New Zealand-based medical device company pioneering non-invasive wearable diagnostics for gastrointestinal disorders. Founded in 2018, the company has developed a novel platform combining a wearable abdominal patch with cloud-based digital biomarkers to enable real-time, ambulatory monitoring of gastric function. Unlike traditional invasive tests such as gastroscopy or manometry, Alimetry’s solution offers a patient-friendly, cost-effective approach to diagnosing conditions like gastroparesis, functional dyspepsia, and chronic nausea. The company has reached commercial stage, indicating market traction and regulatory approvals in certain regions. With a focus on digital health and diagnostics, Alimetry addresses a significant unmet need in gastroenterology, where millions of patients suffer from delayed or inaccurate diagnoses. The platform has the potential to reduce healthcare costs and improve patient outcomes by enabling earlier detection and personalized treatment. While the company remains private and its funding details are undisclosed, its innovative technology and market positioning suggest strong growth potential. However, as a relatively early commercial entity, Alimetry faces challenges in scaling adoption, securing reimbursement, and competing with established diagnostic modalities. The next 12-24 months will be critical for demonstrating clinical utility and expanding market access.

Upcoming Catalysts (preview)

• Q1 2027FDA 510(k) clearance for expanded indications in gastroparesis or functional dyspepsia70% success
• H2 2026Strategic partnership with a major GI pharmaceutical or diagnostic company for distribution50% success
• Q4 2026Publication of pivotal clinical trial results demonstrating diagnostic accuracy vs. standard of care80% success